cigna glp-1 program drops coverage of obesity drugs for its own employees Cigna is making GLP-1 coverage

These conditions include type 2 diabetes mellitus (T2DM), cardiovascular disease, and metabolic dysfunction-associated steatotic liver disease/steatohepatitis (MASLD/MASH), among others [2]

doi: 10.1007/s40262-020-00976-x [DOI] [PMC free article] [PubMed] [Google Scholar] 141.Xie P, Abildlund MT, Baekdal TA, et al

This expanding science reinforces that GLP-1 medications arent just a fad they may be a foundational shift in treating chronic metabolic conditions

Peripheral IR primarily involves reduced insulin-mediated glucose uptake by skeletal muscle and adipose tissue, driven by defects in the insulin receptor substrate and downstream signaling pathways such as phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt), leading to diminished translocation of glucose transporter type 4 (SLC2A4/GLUT4) and glucose uptake [5]

Published 2026 Jan 16

Stay well hydrated, especially during the first few weeks of treatment